Online citations, reference lists, and bibliographies.
← Back to Search

A Randomized, Controlled, Phase II Trial Comparing Escalating Doses Of Subcutaneous Interleukin-2 Plus Antiretrovirals Versus Antiretrovirals Alone In Human Immunodeficiency Virus-infected Patients With CD4+ Cell Counts >/=350/mm3.

M. Losso, W. Belloso, S. Emery, J. Benetucci, P. Cahn, M. Lasala, G. Lopardo, H. Salomón, M. Saracco, E. Nelson, M. Law, R. Davey, M. Allende, H. Lane
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
A total of 73 patients with baseline CD4+ cell counts >/=350 cells/mm3 who were receiving combination antiretroviral therapy (ART) were randomized to receive subcutaneous interleukin-2 (IL-2; n=36) in addition to ART or to continue ART alone (n=37). Subcutaneous IL-2 was delivered at 1 of 3 doses (1.5 million international units ¿MIU, 4.5 MIU, and 7.5 MIU per dose) by twice-daily injection for 5 consecutive days every 8 weeks. After 24 weeks, the time-weighted mean change from baseline CD4+ cell count was 210 cells/mm3 for recipients of subcutaneous IL-2, compared with 29 cells/mm3 for recipients of ART alone (P<.001). There were no significant differences between treatment groups for measures of plasma human immunodeficiency virus RNA (P=.851). Subcutaneous IL-2 delivered at doses of 4.5 MIU and 7.5 MIU resulted in significant increases in CD4+ cell count (P=.006 and P<.001, respectively), compared with that seen in control patients. These changes were not significant in the 1.5 MIU dose group compared with that in the control patients (P=.105). Side effects that occurred from subcutaneous IL-2 administration were generally low grade, of short duration, and readily managed in an outpatient environment.
This paper references
10.1056/NEJM199503023320904
Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.
J. Kovacs (1995)
10.1093/INFDIS/173.2.321
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
A. Kelleher (1996)
10.1056/NEJM199610313351803
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
J. Kovacs (1996)
10.1038/NM0597-533
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
M. Connors (1997)
10.1086/513971
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.
R. Davey (1997)
10.1126/SCIENCE.277.5322.112
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
B. Autran (1997)
10.1086/515653
Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.
A. Carr (1998)
10.1097/00002030-199814000-00015
Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV‐1 infection
J. Giorgi (1998)
10.1097/00002030-199813000-00002
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
R. D. de Boer (1998)
10.1086/515591
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
M. Lederman (1998)
10.1086/314678
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.
R. Davey (1999)
10.1097/00002030-199902040-00008
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
N. Pakker (1999)
10.1016/S0140-6736(98)07345-0
Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial
Y. Lévy (1999)



This paper is referenced by
10.1038/s41598-019-43530-x
Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials
S. H. Mahmoudpour (2019)
10.1002/14651858.CD009818.pub2
Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults
Jennifer Onwumeh (2017)
10.1111/imr.12083
Immune interventions in HIV infection
G. Carcelain (2013)
10.1016/j.molimm.2013.04.008
Promoting immunity during chronic infection--the therapeutic potential of common gamma-chain cytokines.
Jesse G. Toe (2013)
10.2165/10898620-000000000-00000
Role of Interleukin-2 in Patients with HIV Infection
S. Pett (2012)
Immune reconstitution in HIV-1 infection : the effects of antiretroviral and immune therapy
A. Sullivan (2011)
10.1016/J.REVMED.2011.02.011
Stratégies de restauration immunitaire chez les patients infectés par le virus de l’immunodéficience humaine
S. Sahali (2011)
10.2217/imt.10.91
Immunotherapeutic restoration in HIV-infected individuals.
J. Kim (2011)
10.1371/journal.pone.0009334
Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study
J. Tavel (2010)
10.1007/s10875-010-9432-3
IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the Periphery
L. Ndhlovu (2010)
Title IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD 4 + T ( TH 17 ) Cells in the Periphery Permalink
L. Ndhlovu (2010)
10.1056/NEJMoa0903175
Interleukin-2 therapy in patients with HIV infection.
D. Abrams (2009)
Prospectsforantisensepeptide nucleicacid(PNA)therapiesfor HIV
V. Pandey (2009)
Untersuchungen zur Aktivität Natürlicher Killerzellen gegenüber Zytomegalievirus-infizierten Targetzellen: Zytotoxizität in Hinblick auf die Expression von Oberflächenmolekülen
Ä. Direktor (2009)
10.1525/jer.2009.4.3.89
Benefits and Burdens of Participation in a Longitudinal Clinical Trial
J. Lazovski (2009)
10.1517/14712590903052877
Prospects for antisense peptide nucleic acid (PNA) therapies for HIV
V. Pandey (2009)
10.1086/599989
Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).
J. Molina (2009)
10.1157/13114392
Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART.
M. Crespo (2008)
10.1089/oli.2008.0152
Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome.
Alok Upadhyay (2008)
10.1089/AID.2007.0209
Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy.
U. Sriram (2007)
10.1097/QAD.0b013e3282703825
Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048–079 Trials)*
C. Durier (2007)
10.1001/ARCHINTE.167.6.597
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
R. Mitsuyasu (2007)
10.1097/01.COH.0000194106.12816.b1
The CD4 lymphocyte count and risk of clinical progression
A. Phillips (2006)
10.1371/journal.pctr.0010003
A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study
M. Youle (2006)
10.2174/138161206777442119
Therapeutic AIDS vaccines.
A. Bourinbaiar (2006)
A review of the expanded use of co-trimoxazole in HIV-infected Africans
D. Spencer (2006)
10.1097/01.qai.0000225319.59652.1e
A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm3 After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102
K. Henry (2006)
Virological response without CD4 recovery. A case of disappearing soldiers - Can basic science help?
A. Madide (2006)
10.1592/phco.25.1.86.55629
The Use of Interleukin‐2 in Human Immunodeficiency Virus Infection
Jaime P Anaya (2005)
Immune reconstitution in HIV-infected children on antiretroviral therapy
S. Gracía (2005)
10.4049/jimmunol.174.4.1913
Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251
J. Nacsa (2005)
10.1097/01.qai.0000182848.45722.b7
Quality of Life in a Clinical Trial of Highly Active Antiretroviral Therapy Alone or With Intravenous or Subcutaneous Interleukin-2 Administration
B. Martin (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar